InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,428.00
(
0.55%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.56
(
1.12%
)
Bitcoin
64,269.45
(
1.49%
)
Post# of 253211
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120490
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: randychub post# 219754

Friday, 06/22/2018 10:34:07 AM

Friday, June 22, 2018 10:34:07 AM

Post# of 253211

RVNC—For each new indication, will the FDA continue to require the long term safety trial?

No. The rationale for a separate safety study to support the CD indication is that the CD dose is as much as 10x higher than the dose for glabellar lines.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up